News
Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...
Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.
Results for the second quarter were a bit better than expected. Non-GAAP earnings were $2.13 per share, better than the $2.02 ...
Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...
Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback